54 results
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
to generate revenues, which is dependent upon maintaining significant market acceptance among physicians, patients and healthcare payors;
our ability … , including potential changes in healthcare laws and regulations;
our financial performance and our ability to effectively manage our anticipated growth;
our
8-K
IMCR
Immunocore Holdings plc
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 9:00 a.m. PT. A copy of the presentation is attached as Exhibit 99.2 to this Current Report … . Morgan Healthcare Conference will also be available in the “Investors/Media” section of the Company’s website at www.immunocore.com. The Company’s
20-F
2020 FY
IMCR
Immunocore Holdings plc
25 Mar 21
Annual report (foreign)
7:01am
may establish; and
inability of clinical sites to enroll patients as healthcare capacities are required to cope with natural disasters, epidemics … patients, principal investigators and healthcare employees. The COVID-19 pandemic could also affect the operations of our CROs or CMOs, which may result
DRS/A
IMCR
Immunocore Holdings plc
19 Nov 20
Draft registration statement (amended)
12:00am
, licensing agreements or other arrangements that we may establish; and
inability of clinical sites to enroll patients as healthcare capacities … investigators and healthcare employees. The COVID-19 pandemic could also affect the operations of our CROs or CMOs, which may result in delays
DRS
kuzgsoi
17 Nov 20
Draft registration statement
12:00am
6-K
EX-99.2
eytxwcw415
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
8-K
EX-99.1
l9oupk8e88n0k4yw6e8
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.2
1q0y8fukqz4
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
wjloc
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.2
nie7i2 gge21gks3gqo1
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.2
4dxbk
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
424B4
5tnshqbcc7p 5x5b6
8 Feb 21
Prospectus supplement with pricing info
8:36am
F-1
sz0 aidvsmfx
15 Jan 21
Registration statement (foreign)
4:57pm
6-K
EX-99.1
r4map7jc
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
F-1/A
0r0x66xlx8oxi bg6
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
F-1/A
q2cq31n092upn1msa2vb
1 Feb 21
Registration statement (foreign) (amended)
6:21am
6-K
EX-99.1
yfg1y5
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
17k409aj0 16
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.3
pkg7j9etjohwz
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am